Organization | PharmaJet, Inc.

PharmaJet, Inc. Report issue

For profit Phase 1 Phase 2 Phase 4

Founded: Golden CO United States (2005)

Status: No NME R&D (2005)

Organization Overview

First Clinical Trial

2012

NCT01644149

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

PharmaJet, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

inactivated influenza vaccine (3 trials)

Drugs in Phase 2 Trials (2)

bi 1361849 (1 trial)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

Drugs in Phase 1 Trials (1)

venezuelan equine encephalitis virus dna vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Influenza, Human (Phase 4)

Lung Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 4